Axogen/$AXGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Axogen
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Ticker
$AXGN
Sector
Primary listing
Employees
452
Headquarters
Website
Axogen Metrics
BasicAdvanced
$736M
-
-$0.10
0.99
-
Price and volume
Market cap
$736M
Beta
0.99
52-week high
$21.00
52-week low
$9.22
Average daily volume
945K
Financial strength
Current ratio
4.14
Quick ratio
2.32
Long term debt to equity
60.615
Total debt to equity
62.583
Interest coverage (TTM)
0.22%
Profitability
EBITDA (TTM)
8.649
Gross margin (TTM)
74.27%
Net profit margin (TTM)
-2.29%
Operating margin (TTM)
0.84%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
0.54%
Return on equity (TTM)
-4.48%
Valuation
Price to revenue (TTM)
3.565
Price to book
6.52
Price to tangible book (TTM)
6.89
Price to free cash flow (TTM)
209.156
Free cash flow yield (TTM)
0.48%
Free cash flow per share (TTM)
0.076
Growth
Revenue change (TTM)
17.17%
Earnings per share change (TTM)
-73.42%
3-year revenue growth (CAGR)
16.61%
10-year revenue growth (CAGR)
25.58%
3-year earnings per share growth (CAGR)
-48.62%
10-year earnings per share growth (CAGR)
-18.44%
What the Analysts think about Axogen
Analyst ratings (Buy, Hold, Sell) for Axogen stock.
Bulls say / Bears say
Axogen delivered second quarter 2025 revenue of $56.7 million, an 18.3% year-over-year increase, and raised its full-year revenue guidance to at least 17% growth to $219 million, underscoring robust commercial momentum in peripheral nerve repair solutions. (GlobeNewswire)
The company’s gross margin expanded to 74.2% in Q2 2025, up from 73.8% a year earlier and 71.9% in the prior quarter, reflecting improved production efficiencies and operational leverage. (GlobeNewswire)
Axogen completed key regulatory milestones for its Avance® Nerve Graft BLA — including a late-cycle meeting, pre-licensing inspection, and sponsor inspection — positioning the product for potential FDA approval on its September 5, 2025 goal date. (GlobeNewswire)
Canaccord Genuity and Jefferies both cut their price targets on Axogen to $12 (from $22) and $21 (from $30), respectively, signaling analyst concerns over the company’s valuation and medium-term growth outlook. (Reuters)
An FDA decision delay on the Avance® Nerve Graft, now expected under a December 5, 2025 Prescription Drug User Fee Act review date, has introduced uncertainty around the timing of approval and potential revenue ramp. (Investors.com)
In Q1 2025, Axogen reported a GAAP loss of $0.02 per share despite topping revenue estimates, highlighting volatility in quarterly profitability as the company invests heavily in R&D and commercialization. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Axogen Financial Performance
Revenues and expenses
Axogen Earnings Performance
Company profitability
Axogen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Axogen stock?
Axogen (AXGN) has a market cap of $736M as of October 12, 2025.
What is the P/E ratio for Axogen stock?
The price to earnings (P/E) ratio for Axogen (AXGN) stock is 0 as of October 12, 2025.
Does Axogen stock pay dividends?
No, Axogen (AXGN) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Axogen dividend payment date?
Axogen (AXGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Axogen?
Axogen (AXGN) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.